Cryo-Cell International Inc. CCEL
4.24
0.21
5.21%
as of 25 Sep
- Market cap
- $32.5M
- P/E
- 0.0×
Follow CCEL
| May '26 | Feb '26 | Nov '25 | Aug '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.92 | 0.84 | 1.02 | 1.20 | |
P/FCF ratio |
6.16 | 7.36 | 8.24 | 7.87 | |
P/Operating CF |
15.49 | 40.54 | 25.07 | 14.99 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.13 | 1.06 | 1.24 | 1.46 | |
EV/EBITDA |
27.30 | 21.01 | 20.99 | 8.07 | |
EV/Operating CF |
5.56 | 6.42 | 7.17 | 7.27 | |
EV/FCF |
7.56 | 9.26 | 10.08 | 9.57 | |
Quick Ratio |
0.63 | 0.55 | 0.51 | 0.54 | |
Current Ratio |
0.71 | 0.62 | 0.59 | 0.63 | |
Net Debt/EBITDA |
3.18 | 6.14 | (1.98) | 3.62 | |
Debt/Assets |
13.31% | 15.98% | 16.96% | 18.06% | |
Debt/Equity |
(0.46) | (0.53) | (0.56) | (0.77) | |
Asset Turnover |
0.50 | 0.50 | 0.50 | 0.50 | |
Operating CF/Net income |
3.33 | 13.84 | (0.34) | 3.39 | |
Capex/Depreciation |
(0.09) | (0.19) | (0.20) | (0.11) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1.28% | 0.86% | 1.08% | 0.79% | |
Selling, General and Administrative Expense of Revenue |
59.39% | 65.23% | 69.47% | 49.53% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.04 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(2.35) | (2.58) | (2.14) | (1.74) | |
Graham Number |
3.88 | 4.14 | 4.01 | 1.70 | |
Earnings Yield |
(8.57%) | (10.19%) | (7.79%) | (1.48%) | |
Free Cash Flow Yield |
16.23% | 13.58% | 12.13% | 12.70% | |
Revenue per Share |
0.97 | 0.95 | 0.97 | 0.97 | |
Operating CF per Share |
0.23 | 0.08 | 0.16 | 0.31 | |
Capex per Share |
0.00 | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
0.23 | 0.07 | 0.15 | 0.31 | |
Cash per Share |
0.39 | 0.36 | 0.41 | 0.40 | |
Shareholders Equity per Share |
(2.20) | (2.28) | (2.31) | (1.84) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.20) | (2.28) | (2.31) | (1.84) | |
Free Cash Flow |
1.81 | 0.58 | 1.21 | 2.50 | |
Working Capital |
(4.63) | (6.69) | (8.03) | (6.78) | |
Capital Expenditures |
(0.03) | (0.07) | (0.07) | (0.04) | |
Net Current Asset Value |
(67.16) | (68.21) | (68.58) | (66.33) | |
EV/EBIT |
0.00 | 173.71 | 81.46 | 10.68 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Net Profit Margin |
7.13% | 0.61% | (48.67%) | 9.58% | |
Price to Operating Income |
0.00 | 138.04 | 66.58 | 8.79 | |
| Other line items | |||||
Average Receivables |
6.92 | 7.01 | 7.08 | 6.85 | |
Average Payables |
2.54 | 3.02 | 2.38 | 2.31 | |
Average Inventory |
0.49 | 0.54 | 0.53 | 0.69 | |
Average Assets |
62.57 | 62.63 | 63.20 | 63.05 | |
Average Common Equity |
(16.66) | (16.53) | (15.91) | (12.20) |
Columns are period end dates